Evidence map›Paper›PMID 39712850›Full record

ArticleCureus2024

An Unusual Presentation of Cutaneous Bullous Lupus.

Sara H Buchner, Kiana Malta, Shiyu Wang, Adriana Guevara, Cynthia Glickman, Kim Hookim, Pamela Traisak, Marissa Karpoff, David Feinstein, Hala Eid

Abstract readCase Reports
In one paragraph

Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Sara H BuchnerOrthopedics, Cooper Medical School of Rowan University, Camden, USA.
Kiana MaltaPsychiatry, University of Massachusetts Chan Medical School, Worcester, USA.
Shiyu WangRheumatology, Cooper University Health Care, Camden, USA.
Adriana GuevaraInternal Medicine, Cooper University Health Care, Camden, USA.
Cynthia GlickmanMedicine, Cooper University Hospital, Camden, USA.
Kim HookimPathology, Cooper University Health Care, Camden, USA.
Pamela TraisakRheumatology, Cooper University Health Care, Camden, USA.
Marissa KarpoffRheumatology, Cooper Medical School of Rowan University, Camden, USA.
David FeinsteinRheumatology, Cooper University Hospital, Cooper Medical School, Camden, USA.
Hala EidRheumatology, Cooper University Health Care, Camden, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Drug-induced lupus erythematosus (DILE) is an autoimmune reaction that results in symptoms of polyarthralgia, fever, and cutaneous lesions and other manifestations. Several drugs have been documented to cause this disease, including procainamide, isoniazid, methyldopa, penicillamine, and hydralazine. Systemic lupus erythematosus (SLE) manifestations often occur after the patient has been taking the drug without complications for months to years. Hydralazine, an oral antihypertensive drug, is a well-known cause of DILE; however, clinical presentation is generally limited to classic SLE symptoms such as malar or discoid rash and polyarthralgia. In this case, we will discuss a 75-year-old female patient with actively bleeding oral, nasal, and conjunctival ulcers of unknown origin, eventually found to have bullous lupus erythematosus while on hydralazine for several years. Bullous lupus erythematosus is a rare cutaneous manifestation of SLE that presents with blister-type lesions in patients with a history of SLE. Histologically, bullous lupus erythematosus is characterized by marked epidermal and dermal inflammation, and an inflammatory infiltrate that consists primarily of neutrophils at the base of the bullae. Although hydralazine has been implicated in DILE, it is very rarely noted to have a bullous lupus erythematosus presentation. Given the acuity of patient's presentation and resolution with cessation of hydralazine, it was concluded that hydralazine was the main contributing factor for this patient's multiple hemorrhagic bullous lupus erythematosus lesions.

Indexed as

bullous lesionbullous systemic lupus erythematosus (bsle)drug-induced lupus (dil)hydralazinesystemic lupus erythematosus

Identifiers

PMID39712850
PMCPMC11662370

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.